Amphotericin B Liposome for Injection — Class II drug recall D-0891-2023
Terminated recall by SUN PHARMACEUTICAL INDUSTRIES INC, reported 2023-07-05, distributed nationwide. Subpotent drug
| Recall number | D-0891-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Recalling firm | SUN PHARMACEUTICAL INDUSTRIES INC, Princeton, NJ, United States |
| Recall initiated | 2023-05-30 |
| Classified | 2023-06-29 |
| Reported by FDA | 2023-07-05 |
| Terminated | 2023-12-18 |
| Distributed | Nationwide (US) |
| Quantity | 12,960 vials |
| Reason classes | potency |
| NDC | 62756-0233-01 |
| Lot numbers | BAD0089A, BAD0330A |
| Expiration dates | 2025-01, 2025-07 |
Product
Amphotericin B Liposome for Injection, 50mg/vial, Rx only, Distributed by Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Manufactured by Sun Pharmaceutical Medicare Limited, Baska Ujeti Road, Ujeti, Halol-389350, Gujarat, India, NDC 62756-0233-01
Reason for recall
Subpotent drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0891-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.